NTT-DOCOMO
NTT DOCOMO, INC. announced today its Japan Welcome SIMTM series will introduce Plan 0 (read “plan zero”) to allow overseas visitors in Japan to access the Internet for free via the DOCOMO mobile network, from December 26. The free service will initially be available in Hokkaido and Niigata prefectures, after which other areas will be added sequentially.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171224005006/en/
Along with the addition of Plan 0, Japan Welcome SIM’s Plan 1000 and Plan 1700 will be renamed as Plan S and Plan M respectively, and a Plan L will be newly added for large-volume users of high-speed data communications. These changes will also apply from December 26.
DOCOMO has launched various fee-based plans for Japan Welcome SIM since July, but Plan 0 is the first free plan in the series. Customers can qualify for the free service by viewing designated advertisements in their home countries before visiting Japan. Plan 0 is being offered in collaboration with local governments and business partners that are interested in targeting specific foreign visitors through advertisements and by setting various conditions for service usage, such as application periods, SIM pick-up periods, SIM handover locations, total SIMs to be offered, and more.
Japan Welcome SIM is provided as a 3-in-1 SIM card compatible with regular, micro and nano formats. Access to the DOCOMO network is provided for 15 days under various plans — Plan 0, Plan S, Plan M and Plan L. Plan 0 offers free Internet in exchange for viewing a certain number of video ads and completing a survey prior to arriving in Japan. Ad-free access at 128 Kbps is available for ¥1,080 (Plan S), or high-speed (max. 788 Mbps*1 ) 4G access is available with Plan M (¥1,836 for 600 MB) and Plan L (¥2,376 for 1.2 GB). Users can continue to enjoy the high-speed service by topping up their SIMs for ¥216 (100 MB), ¥756 (500 MB) or ¥1,296 (1 GB). Alternatively, the SIMs can be topped up with free high-speed data through methods such as watching video ads or completing surveys. Even after purchased high-speed data amounts have been used up, access to the network is still available at 128 Kbps for the remainder of the 15-day period.
Japan Welcome SIM applications are accepted in English, Japanese, Chinese, Korean and Thai at https://docomo.prepaid-sim.jp/lp card registration required).
| *1 | The data rate shown is the theoretical maximum downlink speed available in certain locations throughout Japan. Access is provided on a best-effort basis and actual speeds may vary depending on the transmission environment, network traffic, and type of device used. | |
| * |
For information on compatible devices and other conditions of use, please visit https://docomo.prepaid-sim.jp/faq/lp and refer to the applicable FAQ section. |
|
| * | Prices shown include tax. | |
DOCOMO makes stays in Japan more convenient and enjoyable by offering visiting tourists and businesspeople data communication options and a translation service that leverages artificial intelligence and other advanced technologies. DOCOMO also supports the stimulation and revitalization of regional economies through its "+d" initiatives for the creation of new value through collaboration with various partners.
About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator
with over 75 million subscriptions, is one of the world’s foremost
contributors to 3G, 4G and 5G mobile network technologies. Beyond core
communications services, DOCOMO is challenging new frontiers in
collaboration with a growing number of entities (“+d” partners),
creating exciting and convenient value-added services that change the
way people live and work. Under a medium-term plan toward 2020 and
beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate
innovative services that will amaze and inspire customers beyond their
expectations. DOCOMO is listed on stock exchanges in Tokyo (9437) and
New York (DCM). www.nttdocomo.co.jp/english
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171224005006/en/
Contact:
For further information, please contact:
NTT DOCOMO
Mr.
Shin Fujioka or Ms. Yurina Toda
Smart-life Planning Department
Tel:
+81-3-5156-2748
Fax: +81-3-3509-6201
Website: www.nttdocomo.co.jp/english
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom